# 1. Financial Performance ## A. Key Figures * Revenue from Operations: ₹409.92 Cr (Q3 FY'25-'26) · ₹445.27 Cr (Q3 FY'24-'25) * EBITDA: ₹58.66 Cr (Q3 FY'25-'26) · ₹75.56 Cr (Q3 FY'24-'25) * **PAT:** **₹40 Cr** (Q3 FY'25-'26) · **₹4 Cr** (Q3 FY'24-'25) * **Cash & Liquid Investments:** **>₹250 Cr** * **9-Month EBITDA Margin Run Rate:** **~18%** ## B. Revenue & Growth * **Sharp Top-Line Expansion:** Revenue surged significantly year-on-year, driven equally by volume and price, both showing stable contributions. * **Non-Recurring Revenue Component:** A **₹6 Cr** net economic benefit (NEB) from Bayer in Q3 boosted top-line, though this income stream will cease post-arrangement change. * **Sales Returns Stable:** Returns remained flat YoY at **₹72 Cr**, indicating consistent post-sale dynamics and no material reversal pressure. ## C. Profit & Margins * **Margin Outlook Under Pressure:** Despite strong EBITDA growth, management expects a **100–110 bps annual EBIT margin decline** due to mix and phasing effects. * **Gross Margin Impact Explained:** Recent **200 bps gross margin compression** attributed to one-time NEB accounting, not input cost inflation, preserving underlying cost discipline. * **Confidence in Q4 Recovery:** Management maintains guidance for **24%–25% EBITDA margin in Q4**, despite prior-year one-time benefit, signaling pricing power and cost control. ## D. Balance Sheet * **Strong Liquidity Position:** Cash and liquid assets exceed **₹250 Cr**, with improved debtors and deleveraging from prior bank loan reduction. * **Inventory Build-Up:** Inventory levels increased YoY due to operational scaling and market readiness, partially offset by healthier receivables. ## E. Cash Flow * **Spending Acceleration:** Q3 expenses reached **₹72 Cr**, with 9-month total near **₹220 Cr**, reflecting elevated operational outlays amid growth investments. --- # 2. Product & Segment Performance ## A. Key Figures * **Bayer Molecules Revenue:** **₹25–27 Cr** (9M, majority in Q3) * **Technical Sales:** **₹50 Cr** (9M) · **₹3–4 Cr** (Q3) * **Biologicals Sales:** **<₹2 Cr** (FY'25) ## B. Bayer Molecules * **Core Product Mix:** Herbicides dominate portfolio with **37% share**, followed by Insecticides (**28%**) and Fungicides (**21%**), reflecting established market positioning. * **Strategic Contribution:** Bayer molecules delivered **strong double-digit revenue contribution** in the 9-month period, with significant front-loading in Q3. ## C. Technical Sales * **Seasonal & Structural Trends:** Technical sales showed **sharp sequential decline in Q3**, consistent with off-season dynamics for key products like Bifenthrin, though early Q1 recovery signals seasonal normalization. * **Policy Resilience:** Recent removal of Chinese export rebates on genetic technicals poses **no material risk** to sourcing or competitiveness, given Dhanuka’s **limited exposure** and prior adaptation to glyphosate-related changes. * **B2B Margin Pressure:** Dahej B2B continues to weigh on profitability with **persistently negative EBITDA**, though stable sequentially; structural drag vs. higher-margin B2C operations remains evident. ## D. Biologicals Portfolio * **Limited Current Scale:** Biologicals remain a **negligible revenue contributor**, with biostimulants representing over **80% of the active portfolio**, while one key product faces near-term unavailability. * **Innovation Pipeline:** Three new product launches planned for FY'27, including **two first-in-market 9(3) fungicides** targeting high-value crops (grapes, potato), and a **premium spray efficiency enhancer** for tomato, signaling strategic focus on specialty segments. * **Market-Led Innovation:** Recent launches (Dinkar, Melody, Verdour) and collaborations with **global partners from Japan, Europe, and the US** reflect a shift toward value-added, niche solutions in horticulture-driven markets. --- # 3. Geography & Channel Mix ## A. Key Figures * **Zone-wise Turnover (Q3 FY'25-'26):** **34%** South India · **30%** West India · **25%** North India · **11%** East India * **Bayer Product Revenue:** **₹25–27 Cr** (India only) * Horticulture Production: 340 million metric tons (surpassing food grain milestone) * **Raw Material Sourcing:** **10–15%** direct procurement from China * **Distribution Network:** **6,500 distributors** and **80,000 retailers** served via **41 warehouses** ## B. Domestic Zones * **Regional Demand Divergence:** Agrochemical demand weakened in Q3 due to adverse weather and low farm incomes, with **sharp declines in South and West India** despite stable performance in North and East. * **Seasonal Revenue Concentration:** Peak business spans July–November, with an additional March surge for sugarcane, highlighting high seasonality in revenue realization. * **Crop Mix & Strategic Reach:** Company serves both export-oriented **specialty crops** (grapes, tomato, chilli) and key conventional crops; future growth hinges on expanding presence into every farming region. * **Structural Shift in Agriculture:** Rising horticulture output (34 Cr MT) signals a move toward high-value farming, creating long-term tailwinds for agrochemical demand. ## C. Overseas Expansion * **International Rollout Underway:** Bayer product registration transfers progressing in overseas markets, with sales expected to begin prior to full completion upon distributor appointments. * **New Market Penetration Strategy:** Dhanuka is appointing national distributors in new geographies, while maintaining Bayer’s existing network in India and Nepal. * **China Sourcing Exposure:** While direct Chinese raw material input is 10–15%, indirect exposure remains unquantified due to layered supply chains through Indian suppliers. ## D. Distribution Network * **Integrated Domestic Infrastructure:** Partnerships with **10 global agrochemical leaders** supported by 4 manufacturing units and a robust logistics footprint enable broad market access. * **Logistics Tailwinds:** Improvements in warehousing, cold chain, road connectivity, and tax transit efficiency are enhancing supply chain reliability and sector-wide operating conditions. --- # 4. Manufacturing & Capacity ## A. Key Figures * **MPP-2 CAPEX:** **₹60–70 Cr** (FY'27 estimate) ## B. Dahej Plant Progress * **Commercialization Milestone:** Second product at Dahej commercialized in Q3 FY'26, with full operational status achieved post-delay in difenoconazole production. * **Near-Term Revenue Dislocation:** Q3 revenue significantly below historical levels despite strong utilization and favorable market conditions, due to **production timing shifts into November–December**. * **Path to Profitability:** Dahej on track to become EBITDA positive by FY'27, supported by 80% capacity utilization target and potential exclusive manufacturing deal with **two multinational firms engaged** (Japanese and European). ## C. MPP-2 CAPEX * **Capacity & Product Ramp:** MPP-2 business plan nearing finalization, with 80% utilization expected in FY'27 across three products—**difenoconazole, Bifenthrin, and newly added Iprovalicarb**. * **Margin Enhancement Driver:** Relocation of one product’s manufacturing from Germany to India to lower production costs and improve margin profile. --- # 5. Regulatory & Product Risks ## A. Key Figures * **Revenue Impact:** **₹15 Cr** Q3 loss · **₹49 Cr** 9M loss due to regulatory delays * **Sales Loss:** **~50%** of biological product sales lost over nine months ## B. Approval Delays * **Biological Product Setback:** Significant revenue and volume loss in biostimulants due to regulatory changes, with **four products delayed** amid framework overhaul. * **Path to Recovery:** New regulatory regime favors organized players; **3 of 4 delayed products expected to gain approval by quarter-end**, enabling portfolio relaunch. * **Bayer Product Risk:** Uncertainty remains over government registration timing for key Bayer-derived stimulant, potentially affecting Q1 availability. ## C. Supply Transition * **Transition Vulnerability:** Ongoing reliance on Bayer for supply and **pending registration transfer** creates near-term supply chain risk despite mitigation planning. ## D. Spurious Product Threat * **Regulatory Tailwind:** Draft Pesticide Management Bill welcomed as a **structural advantage for organized players**, with strict penalties on spurious and misbranded products. * **Market Share Opportunity:** Stricter enforcement expected to **disrupt unregulated operators**, creating headroom for **branded players like Dhanuka to expand share**. * **Implementation Challenge:** Effective rollout requires **center-state coordination**, as agriculture regulation is state-controlled, complicating nationwide enforcement. --- # 6. Guidance & Outlook ## A. Key Figures * **Full-Year Revenue Guidance (Bayer Products):** **₹30 Cr** (revised down from ₹40 Cr) * **Technical Sales Growth Outlook:** **10%-20%** * **Gross Margin Target:** **38%** sustainable long-term * **Agrochemical Consumption:** **>600 gm/ha** in India vs. higher global averages ## B. Full Year View * **Recovery Confirmed:** Management asserts the downturn from two consecutive negative quarters is over, with Q4 off to a strong start in agrochemicals. * **Seasonal Momentum:** Positive Rabi outlook supported by healthy wheat crop and paddy demand in South and East India, though Kharif planning awaits key weather forecasts. * **Weather Watch:** El Nino impact remains uncertain; reliable projections expected post-mid-April from IMD and Australian agencies, with historical variability limiting current predictive value. * **Near-Term Headwinds:** Full-year growth expected to be flattish despite Q4 strength, driven by downward revision in Bayer product sales due to poor grape season. ## C. FY27 Expectations * **Balance Sheet Transformation:** Overseas revenue to appear in Dhanuka’s books from Q1 FY27, marking the start of normalization under full control. * **Economic Benefit Phase-Out:** Net economic benefit to discontinue by FY27 and fully cease by FY28 as export accounting integrates into reported results. ## D. Long Term Growth * **Double-Digit CAGR Confidence:** Strategic focus on rural reach, new product launches, technical manufacturing, and international expansion underpins long-term growth outlook. * **Structural Growth Runway:** Low agrochemical penetration (600+ gm/ha) on 15 crore hectares of arable land highlights significant untapped potential. * **Favorable Macro Backdrop:** Rising farmer investments, improved irrigation, and crop monetization support sustained industry tailwinds.